Cellular therapies for liver replacement.
Insufficient donor organs for orthotopic liver transplantation worldwide have urgently increased the requirement for new therapies for acute and chronic liver disease. Whilst none are yet clinically proven there are at least two different approaches for which there is extensive experimental data, some human anecdotal evidence and some data emerging from Phase 1 clinical trials. Both approaches involve bio-engineering. In vivo tissue engineering involves isolated liver cell transplantation into the liver and/or other ectopic sites and in vitro tissue engineering, using an extracorporeal hepatic support system or bioartificial liver. Some questions are common to both these approaches, such as the best cell source and the therapeutic mass required, and are discussed. Others are specific to each approach. For cell transplantation in vivo the initial engraftment and repopulation will make a critical difference to the outcome, and development of markers for transplanted cells has enabled significant advances in understanding, and therefore manipulating, the process. Moreover, the role of immunosuppression is also important and novel approaches to natural immunosuppression are discussed. For use in a bioartificial liver, the ability for hepatocytes to perform ex vivo at in vivo levels is critical. Three dimensional culture improves cell performance over monolayer cultures. Alginate encapsulated cells offer a suitable 3-D environment for a bioartificial liver since they are both easily manipulatable and cryopreservable. The use of cells derived from stem cells or foetal rather than adult liver cells is also emerging as a potential human cell source which may overcome problems associated with xenogeneic cells.
Selden
Clare
C
Centre for Hepatology, Royal Free Campus, Royal Free and University College Medical School, London NW3 2PF, UK. c.selden@rfc.ucl.ac.uk
Hodgson
Humphrey
H
D000818:Animals; D022781:Hepatocytes / Q000637:transplantation*; D006801:Humans; D008099:Liver / Q000254:growth & development* / Q000473:pathology; D008107:Liver Diseases / Q000473:pathology / Q000628:therapy*; D019164:Liver, Artificial; D051379:Mice; D051381:Rats; D033581:Stem Cell Transplantation; D014183:Transplantation, Heterologous